Evolus Stock Forecast, Price & News

Evolus (NASDAQ:EOLS) Frequently Asked Questions

Is Evolus a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evolus stock.
View analyst ratings for Evolus or view top-rated stocks.

How has Evolus' stock price been impacted by COVID-19?

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 6.9% and is now trading at $5.50.
View which stocks have been most impacted by COVID-19.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Evolus.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.18. The company had revenue of $20.58 million for the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative net margin of 162.78% and a negative trailing twelve-month return on equity of 145.33%.
View Evolus' earnings history.

What price target have analysts set for EOLS?

8 brokers have issued twelve-month price objectives for Evolus' stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Evolus' stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 181.8% from the stock's current price.
View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts.

Who are Evolus' key executives?

Evolus' management team includes the following people:

• David Moatazedi, President, Chief Executive Officer & Director (LinkedIn Profile)
• Lauren P. Silvernail, Chief Financial Officer, EVP-Corporate Development
• Rui Avelar, Chief Medical Officer, Head-Research & Development (LinkedIn Profile)
• Dan Stewart, Vice President & General Manager
• Kurt Knab, Vice President-Sales

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Evolus' key competitors?

Some companies that are related to Evolus include DICE Therapeutics (DICE), Crinetics Pharmaceuticals (CRNX), FibroGen (FGEN), GH Research (GHRS), Innoviva (INVA), Prometheus Biosciences (RXDX), Centessa Pharmaceuticals (CNTA), MannKind (MNKD), Avidity Biosciences (RNA), Vectura Group (VEGPF), Revance Therapeutics (RVNC), MacroGenics (MGNX), Day One Biopharmaceuticals (DAWN), CannTrust (CNTTF) and Seres Therapeutics (MCRB).
View all of EOLS's competitors.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO).

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.91%), First Manhattan Co. (3.65%), Geode Capital Management LLC (1.03%), HealthInvest Partners AB (0.54%), Stonepine Capital Management LLC (0.54%) and Goldman Sachs Group Inc. (0.52%). Company insiders that own Evolus stock include Alphaeon 1 Llc, David Moatazedi, Lauren P Silvernail, Medytox Inc, Rui Avelar and Vikram Malik.
View institutional ownership trends for Evolus.

Which institutional investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Invesco Ltd., Two Sigma Investments LP, Squarepoint Ops LLC, California State Teachers Retirement System, Goldman Sachs Group Inc., Citadel Advisors LLC, and New York State Common Retirement Fund. Company insiders that have sold Evolus company stock in the last year include Alphaeon 1 Llc, David Moatazedi, Lauren P Silvernail, Rui Avelar, and Vikram Malik.
View insider buying and selling activity for Evolus or view top insider-selling stocks.

Which institutional investors are buying Evolus stock?

EOLS stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., Stonepine Capital Management LLC, HealthInvest Partners AB, Millennium Management LLC, Castle Hook Partners LP, Trexquant Investment LP, Summit Global Investments, and Dynamic Technology Lab Private Ltd.
View insider buying and selling activity for Evolus or or view top insider-buying stocks.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $5.50.

How much money does Evolus make?

Evolus has a market capitalization of $305.67 million and generates $56.54 million in revenue each year. The company earns $-163.01 million in net income (profit) each year or ($3.78) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 119 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

Where are Evolus' headquarters?

Evolus is headquartered at 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at (949) 284-4555 or via email at [email protected].